Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Conditions are right for biopharma M&A to break out

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 23, 2023 11:46am

156 Views

Post# 35511350

RE:RE:RE:RE:Conditions are right for biopharma M&A to break out

Smaller bolt-on deals – those under US$25 Billion which have an easier time clearing regulatory hurdles – will be attractive, Evaluate says.

Big Pharma's M&A "sweet spot" is between US$5 Billion and US$25 Billion.

ONCY's M&A valuation for a company with an immune molecule platform in pelareorep and with 2 Phase 3 ready clinical trials is between US$10 Billion and US$15 Billion.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing